Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

MANG - Biotest AG: CFO Martin Moller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future.

Company: Biotest AG Date: 2025-03-06 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 News Details 

Ad-hoc | 6 March 2025 09:01

#   

Biotest AG: CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future.

Biotest AG / Key word(s): Personnel  

Biotest AG: CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future.  

  

06-March-2025 / 09:01 CET/CEST  

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.  

The issuer is solely responsible for the content of this announcement.  

  

- - -

**Ad hoc NOTICE  

Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)**

**CFO Martin** **Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future**

  

*Dreieich,* *Germany,* *6* *March* *2025\.* The Board of Management of Biotest AG announces that Chief Financial Officer Martin Möller will terminate his position as CFO as planned at the end of his contract expires on 15 March 2025.

The Supervisory Board has already initiated the search for a suitable successor and aims to fill the position in the near future.

Martin Möller will continue to support Biotest AG in an advisory capacity beyond the end of his contract.

  

Biotest Aktiengesellschaft  

The Board of Management  

Biotest AG  

Landsteinerstr. 5  

D-63303 Dreieich

www.biotest.com

Disclaimer

This document contains forward-looking statements on the overall economic development and the business, earnings, financial and asset situation of Biotest AG and its subsidiaries. These statements are based on the company’s current plans, estimates, forecasts and expectations and are therefore subject to risks and uncertainties that could cause actual developments to differ materially from those anticipated. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and does not assume any obligation to do so.

About Biotest

Biotest [(www.biotest.com)](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=eb5e77480146c5f07e1363e879343f44&application_id=2096222&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3&application_name=news) is a provider of biological therapeutics derived from human plasma. With a value-added chain that extends from preclinical and clinical development to worldwide sales, Biotest has specialized primarily in the areas of clinical immunology, hematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. Biotest has more than 2,500 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German Stock Exchange. Since May 2022, Biotest has been a part of the Grifols Group, headquartered in Barcelona, Spain ( [www.grifols.com](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=3c02e902ed0629e7e5ed4fdfb99d0c55&application_id=2096222&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3&application_name=news) ).

**IR contact**

Dr Monika Baumann (Buttkereit)  

Phone: +49-6103-801-4406  

Mail: ir@biotest.com

**PR contact**

Dirk Neumüller  

Phone: +49-6103-801-269  

Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201  

Preference shares: securities’ ID No. 522723; ISIN DE0005227235  

Listing: Frankfurt (Prime Standard)  

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Contact:

Martin Möller  

Chief Financial Officer  

Biotest AG  

Landsteinerstr. 5  

63303 Dreieich  

Tel. +40 6103 801 2999  

Fax: +49 6103 801 767  

martin.moeller@biotest.com

  

  

End of Inside Information  

- - -

06-March-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.  

Archive at www.eqs-news.com  

- - -

|     |     |
| --- | --- |
| Language: | English |
| Company: | Biotest AG |
|     | Landsteinerstraße 5 |
|     | 63303 Dreieich |
|     | Germany |
| Phone: | 0 61 03 – 8 01-0 |
| Fax: | 0 61 03 – 8 01-767 |
| E-mail: | ir@biotest.com |
| Internet: | www.biotest.com |
| ISIN: | DE0005227235, DE0005227201 |
| WKN: | 522723, 522720 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2096222 |

  

|     |     |
| --- | --- |
|     |     |
| End of Announcement | EQS News Service |

- - -

2096222  06-March-2025 CET/CEST

![fncls.ssp?fn=show_t_gif&application_id=2096222&application_name=news&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2096222&application_name=news&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3)